Ondine Biomedical Inc Total Liabilities
Ondine Biomedical Inc total liabilities. Based on the latest financial reports, Ondine Biomedical Inc (OBI) has total liabilities worth GBX12.17 Million GBX (≈ $1.48K USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Ondine Biomedical Inc's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Ondine Biomedical Inc (2001–2025)
Total liabilities of Ondine Biomedical Inc from 2001 to 2025. This chart illustrates how Ondine Biomedical Inc's total liabilities have evolved over time, based on quarterly financial data.
Ondine Biomedical Inc Competitors by Total Liabilities
The table below lists competitors of Ondine Biomedical Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Moolec Science SA Ordinary Shares
NASDAQ:MLEC
|
USA | $88.21 Million |
|
Town Centre Securities PLC
LSE:TOWN
|
UK | GBX188.89 Million |
|
FRNT Financial Inc
V:FRNT
|
Canada | CA$476.38K |
|
Ivory Properties Group Bhd
KLSE:5175
|
Malaysia | RM206.09 Million |
|
Enersize Oy
ST:ENERS
|
Sweden | Skr692.46K |
|
Flowtech Fluidpower plc
LSE:FLO
|
UK | GBX59.60 Million |
|
IO Biotech Inc
NASDAQ:IOBT
|
USA | $39.05 Million |
|
Panther Securities P L C
LSE:PNS
|
UK | GBX79.81 Million |
Liability Composition Analysis (2001–2025)
This chart breaks down Ondine Biomedical Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Ondine Biomedical Inc (OBI) total assets.
Liquidity & Leverage Metrics
Ondine Biomedical Inc Total Liabilities Ratios Explained
Ondine Biomedical Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.78 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ondine Biomedical Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ondine Biomedical Inc (2001–2025)
The table below shows the annual total liabilities of Ondine Biomedical Inc from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | GBX10.91 Million ≈ $1.33K |
+83.50% |
| 2024-12-31 | GBX5.95 Million ≈ $723.33 |
+62.92% |
| 2023-12-31 | GBX3.65 Million ≈ $443.98 |
-25.91% |
| 2022-12-31 | GBX4.92 Million ≈ $599.23 |
+9.86% |
| 2021-12-31 | GBX4.48 Million ≈ $545.45 |
-87.71% |
| 2020-12-31 | GBX36.46 Million ≈ $4.44K |
+25.80% |
| 2019-12-31 | GBX28.99 Million ≈ $3.53K |
+29.42% |
| 2018-12-31 | GBX22.40 Million ≈ $2.72K |
+84.24% |
| 2017-12-31 | GBX12.16 Million ≈ $1.48K |
+439.10% |
| 2010-12-31 | GBX2.25 Million ≈ $274.35 |
+68.11% |
| 2009-12-31 | GBX1.34 Million ≈ $163.19 |
-16.65% |
| 2008-12-31 | GBX1.61 Million ≈ $195.79 |
-25.50% |
| 2007-12-31 | GBX2.16 Million ≈ $262.81 |
+15.34% |
| 2006-12-31 | GBX1.87 Million ≈ $227.85 |
+151.16% |
| 2005-12-31 | GBX745.61K ≈ $90.72 |
+218.65% |
| 2003-08-31 | GBX233.99K ≈ $28.47 |
+62.35% |
| 2002-08-31 | GBX144.13K ≈ $17.54 |
+148.43% |
| 2001-08-31 | GBX58.02K ≈ $7.06 |
-- |
About Ondine Biomedical Inc
Ondine Biomedical Inc., a life-sciences company, engages in the development of activated antimicrobial therapies for the prevention and treatment of infections in Canada and internationally. Its primary product is Steriwave, a non-invasive, nurse-administered treatment that eliminates harmful bacteria, viruses, and fungi from the nose. In addition, the company offers a pipeline of photodisinfecti… Read more